Business
Ocular Therapeutix™ to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and
About this update from Ocular Therapeutix, Inc.
[{"type":"text","content":" BEDFORD, Mass.--(BUSINESS WIRE)--\nOcular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held April 22-26, 2022 in Washington, D.C.\n\n“We are excited to have such a large presence at this year’s ASCRS which we believe highlights the interest in DEXTENZA® as well as our other ocular surface programs,” commented Michael Goldstein, MD, MBA, President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix. “The data we are presenting includes updates on DEXTENZA, which is commercially available to treat inflammation and pain associated ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and OTX-DED for the treatment of dry eye disease. All of the data being presented continue to demonstrate the breadth of our proprietary hydrogel technology and its potential to meet unmet needs in many areas of the ophthalmic space.”\n\nOcular Therapeutix Presentations at ASCRS:\n\nDEXTENZA® (Post-operative Ocular Inflammation and Pain):\n\n\nTitle: Real-World Safety Analysis of an Intracanalicular Dexamethasone Insert Using the Intelligent Research in Site (IRIS) Registry\nSession Title: Medications (Preoperative, Postoperative, Intraoperative)\nSession Date/Times: Sunday, April 24, 2022 at 1:30 PM-1:35 PM ET\nLocation: WEWCC, Level 1, 143C\nPresenter: Robert T Chang, MD, ABO\n\n\nTitle: Real-World Characteristics of Patients Treated with Intracanalicular Dexamethasone Insert: An IRIS Registry Analysis 2019-2021\nSession Title: Medications (Preoperative, Postoperative, Intraoperative)\nSession Date/Times: Sunday, April 24, 2022 at 1:43 PM-1:48 PM ET\nLocation: WEWCC, Level 1, 143C\nPresenter: Michael Mbagwu, MD\n\n\nDEXTENZA (Allergic Conjunctivitis):\n\n\nTitle: Effects of Punctal Occlusion on Ocular Itching and Conjunctival Redness in Subjects with Allergic Conjunctivitis\nSession Title: Ocular Surface Disease\nSession Date/Times: Monday, April 25, 2022 at 8:28 AM-8:33 AM ET\nLocation: WEWCC, Level 1, 143A\nPresenter: Steven M. Silverstein, MD, FACS, ABO\n\n\nTitle: Sustained 30 Day Effect of an Intracanalicular Dexamethasone Insert for ...